静脉注射/口服莫西沙星和静脉注射头孢曲松/口服头孢呋辛酯治疗院内获得性肺炎的疗效比较

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (4): 424-429.

静脉注射/口服莫西沙星和静脉注射头孢曲松/口服头孢呋辛酯治疗院内获得性肺炎的疗效比较

吴志强

浙江省人民医院药学部,杭州 310014,浙江

收稿日期:2012-09-22 出版日期:2013-04-26 发布日期:2013-04-26
作者简介:吴志强,男,主管药师,研究方向:临床药学。Tel: 13757177350 E-mail: wzhizhi@hotmail.com

A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia

WU Zhi-qiang

Department of Pharmacy,Zhejiang Provincial People's Hospital,Hangzhou 310014, Zhejiang,China

Received:2012-09-22 Online:2013-04-26 Published:2013-04-26

摘要/Abstract

摘要： 目的: 比较莫西沙星和头孢曲松/头孢呋辛酯治疗院内肺炎(HAP)的有效性和安全性。方法: 161例HAP病例随机分为2组,莫西沙星组患者静脉注射 400 mg 莫西沙星,每日一次,3～5 d 后改为口服 400 mg 莫西沙星。头孢曲松组患者静脉注射 2 g 头孢曲松,每日2次,3～5 d 后改为口服 500 mg 头孢呋辛酯,治疗共持续7～14 d。主要的疗效指标是在治疗期结束后7～15 d 内的临床反应,次要观察指标为治疗后31 d内的临床和细菌学反应。结果: 对其中 120 例进行PP分析(每组60例),莫西沙星和头孢曲松组的临床治愈率分别为87% 和83% [95% CI (-9.77,15.96)]。两组次要终点指标相当。两种疗法都有良好的安全性和耐受性。结论: 静脉注射/口服莫西沙星是治疗轻-中度HAP的一种替代疗法。

关键词: 莫西沙星, 头孢曲松, 院内获得性肺炎

Abstract: AIM: To observe the effects of moxifloxacin in treatment of hospital-acquired-pneumonia(HAP) compared with ceftriaxone.METHODS: 161 HAP patients were randomly divided into two groups.One group were given moxifloxacin 400 mg i.v. once daily followed by oral moxifloxacin 400 mg once daily.The other group were given ceftriaxone 2 g i.v. once daily followed by oral cefuroxime axetil 500 mg twice daily.RESULTS: 120 patients were eligible for per protocol efficacy analyses (60 each in the moxifloxacin and the comparator groups). Clinical success rates were 87% for moxifloxacin and 83% for the comparable group [95% CI(-9.77,15.96)].The results for secondary endpoints were similar between 2 groups. Both treatments were safe and well tolerated.CONCLUSION: Moxifloxacin i.v. /oral can be considered as a possible alternative therapy for patients with mild-to-moderate nosocomial pneumonia

Key words: Moxifloxacin, Ceftriaxone, Hospital-acquired pneumonia

中图分类号:

R563.1

吴志强. 静脉注射/口服莫西沙星和静脉注射头孢曲松/口服头孢呋辛酯治疗院内获得性肺炎的疗效比较[J]. 中国临床药理学与治疗学, 2013, 18(4): 424-429.

WU Zhi-qiang. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 424-429.

参考文献

[1] Tiengrim S, Thamlikitkul V.Inhibitory activity of fermented milk with Lactobacillus casei strain Shirota against common multidrug-resistant bacteria causing hospital-acquiredinfections[J].J Med Assoc Thai,2012,95(12):S1-5.
[2] Hoffken G, Barth J, Rubinstein E, et al. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia[J]. Infection,2007 ,35(6):414-420.
[3] Samilski JA, Lau TT, Elbe DH, et al.Drug use evaluation of moxifloxacin (avelox) using a hand-held electronic device at a canadian teaching hospital[J].P T, 2012,37(5):291-299.
[4] Novosel TJ, Hodge LA, Weireter LJ, et al.Ventilator-associated pneumonia: depends on your definition[J].Am Surg,2012,78(8):851-854.
[5] Brand C, Tropea J, Gorelik A et al.An adverse event screening tool based on routinely collected hospital-acquired diagnoses[J]. Int J Qual Health Care,2012,24(3):266-278.
[6] 王友多.莫西沙星、左氧氟沙星和环丙沙星治疗下呼吸道感染的疗效及成本-效果分析[J]. 中国临床药理学与治疗学,2012,24(2):247-249.
[7] 官莹.新氟喹诺酮类药物在肺部感染中的合理应用[J].临床肺科杂志,2007,12 (08):885-886.
[8] Yokota S, Ohkoshi Y, Fuji N.Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates[J]. Diagn Microbiol Infect Dis,2009, 65(3):76-80.
[9] Siempos LI, Dimopoulos G, Korbila LP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis[J]. Eur Respir J, 2007,29(3): 1127-1137.
[10] 张幸,孙勉.莫西沙星治疗急性下呼吸道感染的临床观察[J].临床肺科杂志,2009,14(05):655-656.